Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News

Latest news

ELCC: PD-L1 expression and association with survival in mesothelioma

31 Mar 2014
ELCC: PD-L1 expression and association with survival in mesothelioma

Therapeutic targeting implications may arise.

Data from the Mayo Clinic, Rochester, USA, shows that a programmed cell death 1 ligand 1 (PD-L1) is expressed in a substantial number of cases with malignant pleural mesothelioma.

To read the rest of this story visit the ESMO site.

Related News

Long-lasting immunotherapy response in stage IV lung cancer with brain metastasis 21 Oct 2024
Neural network models based on clinical characteristics for predicting immunotherapy efficacy in small cell lung cancer 14 Oct 2024
Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer 10 Oct 2024
Timing matters when adding immunotherapy to chemoradiation for patients with limited-stage small cell lung cancer 2 Oct 2024
Leading-edge radiotherapy treatments for people with lung, genitourinary and blood cancers presented at the American Society for Radiation Oncology Annual Meeting 2 Oct 2024
Combination treatment improves response to immunotherapy for lung cancer 25 Sep 2024
FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection 14 Sep 2024
WCLC 2024: Perioperative nivolumab may provide meaningful improvement in event-free survival compared to only neoadjuvant nivolumab plus chemotherapy for resectable NSCLC 9 Sep 2024
Tumour-infiltrating lymphocyte therapy marks a milestone in cancer treatment 19 Jul 2024
Immunotherapy approach shows potential in some people with metastatic solid tumours 12 Jul 2024

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation